V-12c

V-12c: sourced facts only. name: "Herein, we report a novel hybrid ERα/HDAC6 dual-targeting PROTAC V-12c, which selectively degraded ERα and HDAC6 in vitro and in vivo and exhibited superior antiproliferation efficacy across a panel of BC cell lines." [PMID:42411996]; target: "Herein, we report a novel hybrid ERα/HDAC6 dual-targeting PROTAC V-12c, which selectively degraded ERα and HDAC6 in vitro and in vivo and exhibited superior antiproliferation efficacy across a panel of BC cell lines." [PMID:42411996]; target: "Herein, we report a novel hybrid ERα/HDAC6 dual-targeting PROTAC V-12c, which selectively degraded ERα and HDAC6 in vitro and in vivo and exhibited superior antiproliferation efficacy across a panel of BC cell lines." [PMID:42411996]; developer: "Department of Hematology, Zhongnan Hospital of Wuhan University School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China." [PMID:42411996]; modality: "Herein, we report a novel hybrid ERα/HDAC6 dual-targeting PROTAC V-12c, which selectively degraded ERα and HDAC6 in vitro and in vivo and exhibited superior antiproliferation efficacy across a panel of BC cell lines." [PMID:42411996]; stage: "Importantly, V-12c potently suppressed tumor growth in endocrine-resistant BC models, outperforming single-target therapies." [PMID:42411996]